Literature DB >> 20799514

Clinicopathological factors associated to HER-2 status in a hospital-based sample of breast cancer patients in Puerto Rico.

Ana P Ortiz1, Orquídea Frías, Carmen González-Keelan, Erick Suárez, David Capó, Javier Pérez, Fernando Cabanillas, Edna Mora.   

Abstract

Breast cancer is the most common female malignancy in Puerto Rico. Cases with human epidermal growth factor receptor 2 (HER-2) oncoprotein overamplification are associated with aggressive clinical behavior. Given the limited availability of information for Puerto Rico, we aimed to evaluate the prevalence and clinical correlates of HER-2 gene overexpression among a hospital-based female population of breast cancer cases. We analyzed data from 1,049 female patients with invasive breast cancer (diagnosed 2000-2005) at the I. González Martínez Oncologic Hospital and the Auxilio Mutuo Hospital. HER-2 status and other clinical characteristics were retrieved from the hospitals' cancer registries, from the Puerto Rico Central Cancer Registry, and from a review of medical and pathological records. Prevalence odds ratios were estimated with 95% confidence intervals, using logistic regression models to quantify the association between HER-2 status and different clinicophatological factors. The overall prevalence of positive HER-2 expression was 22.5%. In the multivariate logistic regression model, factors significantly associated with HER-2 positivity included a diagnosis age of < 50 years, having a tumor with negative progesterone receptor (PR) status, and having regional disease (p < 0.05). No significant differences in HER-2 positivity were observed by tumor histology or estrogen receptor (ER) status (p > 0.05). This is the most comprehensive epidemiological study to date on HER-2 status in Puerto Rico. The prevalence and correlates of HER-2 overexpression in this study are comparable to those observed in US populations. Study results will aid in the development of breast cancer control strategies in Puerto Rico.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20799514      PMCID: PMC3827955     

Source DB:  PubMed          Journal:  P R Health Sci J        ISSN: 0738-0658            Impact factor:   0.705


  37 in total

1.  Breast cancer racial gap examined: no easy answers to explain disparities in survival.

Authors:  Brian Vastag
Journal:  JAMA       Date:  2003-10-08       Impact factor: 56.272

2.  The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.

Authors:  E K Latta; S Tjan; R K Parkes; F P O'Malley
Journal:  Mod Pathol       Date:  2002-12       Impact factor: 7.842

3.  Her-2/neu oncogene expression in Puerto Rican females with breast cancer.

Authors:  R Peredo; G Sastre; J Serrano; R Hunter Mellado
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2001-09       Impact factor: 1.770

Review 4.  Racial differences in genetic factors associated with breast cancer.

Authors:  Foluso O Ademuyiwa; Olufunmilayo I Olopade
Journal:  Cancer Metastasis Rev       Date:  2003-03       Impact factor: 9.264

5.  HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors.

Authors:  Sylvie Ménard; Andrea Balsari; Patrizia Casalini; Elda Tagliabue; Manuela Campiglio; Rosaria Bufalino; Natale Cascinelli
Journal:  Clin Cancer Res       Date:  2002-02       Impact factor: 12.531

6.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

7.  Prevalence of steroid receptors and HER 2/neu in breast cancer biopsies of women living in Puerto Rico.

Authors:  Edgardo Colón; José S Reyes; Carmen González Keelan; Consuelo Climent-Peris
Journal:  P R Health Sci J       Date:  2002-12       Impact factor: 0.705

8.  Amplification of the neu (c-erbB-2) oncogene in human mammmary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene.

Authors:  M van de Vijver; R van de Bersselaar; P Devilee; C Cornelisse; J Peterse; R Nusse
Journal:  Mol Cell Biol       Date:  1987-05       Impact factor: 4.272

9.  African-American/White differences in breast carcinoma: p53 alterations and other tumor characteristics.

Authors:  Beth A Jones; Stanislav V Kasl; Christine L Howe; Mary Lachman; Robert Dubrow; Mary McCrea Curnen; Hosanna Soler-Vila; Alicia Beeghly; Fenghai Duan; Patricia Owens
Journal:  Cancer       Date:  2004-09-15       Impact factor: 6.860

10.  Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.

Authors:  Gottfried Konecny; Giovanni Pauletti; Mark Pegram; Michael Untch; Sugandha Dandekar; Zuleima Aguilar; Cindy Wilson; Hong-Mei Rong; Ingo Bauerfeind; Margret Felber; He-Jing Wang; Malgorzata Beryt; Ram Seshadri; Herrmann Hepp; Dennis J Slamon
Journal:  J Natl Cancer Inst       Date:  2003-01-15       Impact factor: 13.506

View more
  2 in total

1.  Prevalence of breast and ovarian cancer subtypes in Hispanic populations from Puerto Rico.

Authors:  Ariel Rodriguez-Velazquez; Rosa Velez; Jean Carlo Lafontaine; Claudia B Colon-Echevarria; Rocio D Lamboy-Caraballo; Ingrid Ramirez; Adalberto Mendoza; Patricia Casbas-Hernandez; Guillermo N Armaiz-Pena
Journal:  BMC Cancer       Date:  2018-11-27       Impact factor: 4.430

2.  Breast cancer molecular subtypes and survival in a hospital-based sample in Puerto Rico.

Authors:  Ana Patricia Ortiz; Orquidea Frías; Javier Pérez; Fernando Cabanillas; Lisa Martínez; Carola Sánchez; David E Capó-Ramos; Carmen González-Keelan; Edna Mora; Erick Suárez
Journal:  Cancer Med       Date:  2013-04-18       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.